AI Blood Test Analyzer: 2.5M Tests Analyzed | Kantesti 2026

AI Blood Test Analyzer Free – Lab Interpretation, Made in Germany > Blog > Articles > AI Blood Test Analyzer: 2.5M Tests Analyzed | Kantesti 2026

January 2026 Global Health Intelligence Report

AI Powered Analysis of 2.5 Million Blood Test Results Reveals Critical Health Patterns Across 10 Countries

📊 2.5M Blood Tests Analyzed 🌍 10 Countries 🔬 Peer Reviewed ✓ CE Marked

Peer-Reviewed Research Publication

Cite This Research

Digital Object Identifier (DOI)

10.5281/zenodo.18175532

ResearchGate Publication

View Full Research Paper

Download Full Report

PDF (2.5 MB)

📋 How to Cite This Report

Klein, T., Mitchell, S., & Weber, H. (2026). January 2026 Global Health Intelligence Report: AI-Powered Analysis of 2.5 Million Blood Test Results Reveals Critical Health Patterns Across 10 Countries. Kantesti AI. DOI: 10.5281/zenodo.18175532

Thomas Klein MD, Chief Medical Officer at Kantesti AI, board-certified clinical hematologist and author of this global health report

Thomas Klein, MD

Chief Medical Officer, Kantesti AI

Dr. Thomas Klein is a board certified clinical hematologist with over 15 years of experience in laboratory medicine and AI assisted diagnostics. As Chief Medical Officer at Kantesti AI, he leads the clinical validation processes and oversees the medical accuracy of our 2.78 trillion parameter neural network. Dr. Klein is affiliated with Istanbul Nisantasi University, Department of Hematology, and has published extensively on biomarker analysis and population specific reference range optimization.

ResearchGate Google Scholar
2.5M Blood Tests Analyzed
10 Countries Covered
127+ Biomarkers Tracked
2.78T AI Parameters
98.7% Clinical Accuracy

Executive Summary

As Chief Medical Officer at Kantesti AI, I am pleased to present our most comprehensive global health intelligence report to date. Throughout 2025 and into early 2026, our platform has analyzed over 2.5 million anonymized blood test results from users across 10 countries, providing unprecedented insights into regional health patterns and disease prevalence. This report, reviewed and validated by our Medical Advisory Board including Dr. Sarah Mitchell and Prof. Dr. Hans Weber, represents a significant contribution to our understanding of global health trends in the context of AI powered diagnostics.

The findings presented in this report are based on data collected from January 2025 through January 2026, processed using our proprietary 2.78 trillion parameter neural network. Unlike competitors who rely on third party APIs, our AI blood test analyzer free platform utilizes a purpose built architecture specifically designed for biomarker interpretation, achieving clinical accuracy rates between 98.7% and 99.84% as validated through independent triple blind studies.

This research aligns with global health monitoring initiatives established by the World Health Organization and contributes valuable data to our collective understanding of non communicable disease prevalence across developed nations. Our methodology adheres to guidelines established by the European Centre for Disease Prevention and Control and incorporates reference ranges validated against standards from national health institutions in each country studied.

⚠️ Important Medical Disclaimer

The information presented in this report is intended for educational and research purposes only. While our AI blood test analysis provides valuable health insights, it does not replace professional medical consultation. Always consult with qualified healthcare providers for medical diagnosis, treatment decisions, and personalized health advice. The disease prevalence data presented reflects patterns observed in our user population and may not represent general population statistics.

Key Research Findings

Our analysis of 2.5 million blood test results has revealed several critical patterns that warrant attention from both healthcare professionals and individuals monitoring their health. These findings demonstrate the power of AI driven lab results interpretation online in identifying population level health trends.

🫀

Cardiovascular Disease Remains the Primary Concern

Blood biomarkers indicating cardiovascular risk were detected in 33% to 45% of analyzed samples across all 10 countries, with the United States showing the highest prevalence at 44.8%.

🩸

Regional Anemia Variations Highlight Nutritional Disparities

Iron deficiency anemia markers showed significant geographic variation, ranging from 14.2% in the Netherlands to 31.5% in Brazil, suggesting distinct nutritional and socioeconomic factors.

📈

Metabolic Syndrome on the Rise in Western Europe

Combined metabolic markers indicating metabolic syndrome showed a concerning 23% average increase compared to 2024 data, particularly pronounced in Belgium and Germany.

🦋

Thyroid Dysfunction Underdiagnosed Globally

Our AI identified subclinical thyroid abnormalities in 18.7% of samples where users reported no prior thyroid diagnosis, highlighting the value of comprehensive screening.

🔬

Early Detection Patterns Validated

In 27.3% of cases where our AI flagged potential concerns, users subsequently reported receiving medical attention for conditions detected through our analysis.

💊

Vitamin D Deficiency Widespread in Northern Countries

Northern European countries showed vitamin D insufficiency rates exceeding 45%, with the Netherlands, Belgium, and Germany most affected during winter months.

Global Disease Prevalence Patterns Across All 10 Countries

Cardiovascular Disease Markers 38.9%
Type 2 Diabetes Indicators 29.4%
Anemia and Iron Deficiency 22.6%
Metabolic Syndrome 21.3%
Thyroid Disorders 17.8%
Vitamin Deficiencies 15.2%
Kidney Function Abnormalities 11.7%
Liver Function Concerns 9.4%
🇺🇸

United States

North America's Largest Healthcare Market

387,420 Blood Tests Analyzed

Health Landscape Analysis

The United States represents our largest user base, providing a robust dataset for understanding health patterns in a highly developed healthcare system. Our analysis of 387,420 blood test results reveals concerning trends in cardiovascular and metabolic health that align with data from the Centers for Disease Control and Prevention.

American users showed the highest cardiovascular disease marker prevalence among all countries studied at 44.8%, significantly above the global average of 38.9%. This finding correlates with the CDC's reports on heart disease remaining the leading cause of death in the United States. Our AI blood test analyzer identified elevated LDL cholesterol, triglycerides, and inflammatory markers such as C reactive protein in a substantial portion of samples.

Type 2 diabetes indicators were present in 34.2% of American samples, the second highest rate in our study. The combination of elevated fasting glucose, HbA1c levels, and insulin resistance markers suggests that prediabetes and undiagnosed diabetes remain significant concerns. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that 38% of American adults have prediabetes, closely aligning with our findings.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Elevated cholesterol, triglycerides, and inflammatory markers
    44.8%
  • 2
    Type 2 Diabetes Indicators Elevated fasting glucose, HbA1c, and insulin resistance
    34.2%
  • 3
    Metabolic Syndrome Combined metabolic dysfunction markers
    28.7%
  • 4
    Liver Function Abnormalities Elevated ALT, AST, and GGT enzymes
    16.3%
  • 5
    Thyroid Dysfunction TSH and thyroid hormone imbalances
    14.9%

🩺 Clinical Recommendations for American Users

  • Schedule comprehensive lipid panel screenings annually if over 40 or with family history of heart disease
  • Request HbA1c testing during routine checkups to monitor long term blood glucose trends
  • Consider Mediterranean diet patterns shown to reduce cardiovascular risk markers
  • Implement regular physical activity targeting 150 minutes of moderate exercise weekly
  • Discuss liver enzyme elevations with healthcare providers, particularly if using medications or supplements
  • Monitor blood pressure regularly given strong correlation with cardiovascular biomarkers

United States Health Markers Distribution

Cardiovascular 44.8%
Diabetes 34.2%
Metabolic Syndrome 28.7%
Liver Function 16.3%
Thyroid 14.9%
Kantesti AI United States blood test analysis showing disease prevalence rates with cardiovascular disease at 44.8 percent diabetes at 34.2 percent metabolic syndrome at 28.7 percent liver function abnormalities at 16.3 percent and thyroid dysfunction at 14.9 percent based on 387420 analyzed samples from December 2025 data
Figure 1: AI powered analysis of 387,420 American blood test results (December 2025 data) reveals cardiovascular disease markers in 44.8% of samples, the highest rate among all 10 countries studied, followed by diabetes indicators at 34.2% and metabolic syndrome at 28.7%.
Kantesti AI United States health trends comparison chart showing year over year changes in disease prevalence between 2024 and 2025 with cardiovascular markers increasing 3.2 percent diabetes increasing 4.7 percent and metabolic syndrome rising 5.1 percent among American blood test users
Figure 2: Year over year analysis of American blood test results shows concerning upward trends in metabolic conditions with metabolic syndrome markers increasing 5.1% and diabetes indicators rising 4.7% compared to 2024 data.
🇩🇪

Germany

Europe's Largest Economy and Healthcare System

342,180 Blood Tests Analyzed

Health Landscape Analysis

Germany, home to Kantesti AI's headquarters in Cologne, provides particularly detailed insights given our strong user adoption in the DACH region. Analysis of 342,180 blood test results from German users reveals a distinct health profile characterized by high cardiovascular disease markers combined with notable thyroid dysfunction patterns. Data from the Robert Koch Institute supports our findings regarding chronic disease prevalence.

German users demonstrated cardiovascular disease markers at 41.3%, the second highest after the United States. However, our lab results interpretation system identified a unique pattern in German samples, with elevated homocysteine levels appearing more frequently than in other countries. This B vitamin metabolism marker, present in 23.4% of German samples, suggests potential benefit from enhanced B12 and folate monitoring.

A distinctive finding in German data is the elevated thyroid dysfunction rate of 19.8%, the highest among all studied countries. This may relate to Germany's historical classification as an iodine deficient region, though supplementation programs have improved general iodine status. Our AI blood test analysis detected subclinical hypothyroidism patterns warranting medical follow up in a significant portion of users who reported no prior thyroid concerns.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Lipid abnormalities and homocysteine elevation
    41.3%
  • 2
    Type 2 Diabetes Indicators Glucose metabolism dysfunction markers
    27.6%
  • 3
    Metabolic Syndrome Combined cardiometabolic risk factors
    24.8%
  • 4
    Thyroid Dysfunction TSH abnormalities and thyroid autoantibodies
    19.8%
  • 5
    Vitamin D Deficiency Insufficient 25-hydroxyvitamin D levels
    18.4%

🩺 Clinical Recommendations for German Users

  • Request comprehensive thyroid panels including TSH, free T4, and thyroid antibodies
  • Consider homocysteine testing alongside standard cardiovascular markers
  • Ensure adequate vitamin D supplementation during winter months, targeting 2000 to 4000 IU daily
  • Discuss B12 and folate status with healthcare providers given elevated homocysteine patterns
  • Monitor iodine intake through diet or supplementation as recommended by your physician
  • Participate in Germany's preventive health checkup programs offered through statutory health insurance

Germany Health Markers Distribution

Cardiovascular 41.3%
Diabetes 27.6%
Metabolic Syndrome 24.8%
Thyroid 19.8%
Vitamin D Deficiency 18.4%
Kantesti AI Germany blood test analysis showing disease prevalence rates with cardiovascular disease at 41.3 percent diabetes at 27.6 percent metabolic syndrome at 24.8 percent thyroid dysfunction at 19.8 percent the highest thyroid rate in the study and vitamin D deficiency at 18.4 percent based on 342180 analyzed samples from December 2025 data
Figure 3: AI analysis of 342,180 German blood tests (December 2025 data) reveals the highest thyroid dysfunction rate in the study at 19.8% along with elevated homocysteine patterns suggesting B vitamin metabolism concerns unique to the German population.
Kantesti AI Germany specialized analysis focusing on elevated thyroid dysfunction at 19.8 percent and elevated homocysteine levels at 23.4 percent with B vitamin metabolism patterns and recommendations for comprehensive thyroid panels and B12 folate monitoring among German blood test users
Figure 4: Unique analysis of German blood test results reveals elevated homocysteine in 23.4% of samples alongside the highest thyroid dysfunction rate in the study, suggesting specific screening recommendations for B vitamin status and comprehensive thyroid panels.
🇫🇷

France

The French Paradox in Modern Context

289,340 Blood Tests Analyzed

Health Landscape Analysis

France presents a fascinating health profile that partially supports the well documented French Paradox, the observation that French populations historically showed lower cardiovascular mortality despite dietary fat intake. Our analysis of 289,340 blood test results reveals cardiovascular disease markers at 36.7%, notably lower than both the United States and Germany despite similar lifestyle factors. Research from INSERM, France's national health research institute, continues to investigate these protective factors.

French users demonstrated the highest anemia prevalence among Western European countries at 24.3%, with iron deficiency being particularly prominent in women of reproductive age. Our blood test result analyzer identified that 31.2% of French women aged 18 to 45 showed ferritin levels below optimal ranges, suggesting underrecognized iron deficiency that warrants attention.

An unexpected finding in French data is the elevated rate of vitamin B12 deficiency at 12.8%, higher than other Western European nations. This may correlate with dietary patterns or absorption issues and represents an area where our AI powered blood test interpretation service provides valuable early detection.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Generally lower lipid abnormalities than expected
    36.7%
  • 2
    Anemia and Iron Deficiency Low ferritin and hemoglobin levels
    24.3%
  • 3
    Type 2 Diabetes Indicators Glucose regulation abnormalities
    22.1%
  • 4
    Thyroid Dysfunction Subclinical thyroid abnormalities
    16.5%
  • 5
    Vitamin B12 Deficiency Low serum B12 levels
    12.8%

🩺 Clinical Recommendations for French Users

  • Women should request comprehensive iron studies including ferritin, transferrin saturation, and TIBC
  • Consider vitamin B12 testing especially if following vegetarian or vegan dietary patterns
  • Maintain traditional dietary patterns that may contribute to cardiovascular protection
  • Monitor hemoglobin and red blood cell indices during routine health examinations
  • Discuss methylmalonic acid testing if B12 deficiency is suspected despite normal serum levels
  • Utilize France's comprehensive bilan sanguin options available through the healthcare system

France Health Markers Distribution

Cardiovascular 36.7%
Anemia 24.3%
Diabetes 22.1%
Thyroid 16.5%
Vitamin B12 Deficiency 12.8%
Kantesti AI France blood test analysis showing disease prevalence rates demonstrating the French Paradox with cardiovascular disease at only 36.7 percent alongside anemia at 24.3 percent the highest in Western Europe diabetes at 22.1 percent thyroid dysfunction at 16.5 percent and vitamin B12 deficiency at 12.8 percent based on 289340 analyzed samples from December 2025 data
Figure 5: AI analysis of 289,340 French blood tests (December 2025 data) reveals lower cardiovascular markers at 36.7% supporting the French Paradox while identifying the highest anemia rate in Western Europe at 24.3% particularly affecting women of reproductive age.
Kantesti AI France specialized analysis of iron deficiency in women showing 31.2 percent of French women aged 18 to 45 with low ferritin levels and comprehensive iron panel recommendations including ferritin transferrin saturation and TIBC testing for optimal health monitoring
Figure 6: Detailed analysis of French women's blood tests reveals significant iron deficiency patterns with nearly one third of reproductive age women showing suboptimal ferritin levels, highlighting the importance of comprehensive iron studies beyond basic hemoglobin screening.
🇮🇹

Italy

Mediterranean Diet Heartland

256,890 Blood Tests Analyzed

Health Landscape Analysis

Italy's position as the birthplace of the Mediterranean diet provides valuable context for our blood test analysis findings. Our examination of 256,890 Italian blood test results reveals a health profile that demonstrates both the benefits of traditional dietary patterns and emerging concerns related to modernization. The Istituto Superiore di Sanità has documented similar transitional health patterns in recent epidemiological surveys.

Italian users showed cardiovascular disease markers at 35.2%, among the lowest in our study, supporting continued benefits from Mediterranean dietary adherence. However, our AI blood diagnostics identified concerning trends in younger age groups where metabolic syndrome markers approached rates seen in Northern European countries, suggesting generational shifts in dietary and lifestyle habits.

A notable finding specific to Italian data is elevated kidney function marker rates at 13.9%, particularly in regions with historically high salt intake. Our AI blood test interpretation system flagged elevated creatinine and reduced estimated glomerular filtration rate patterns that warrant monitoring, especially in users over 50 years of age.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Relatively favorable lipid profiles
    35.2%
  • 2
    Type 2 Diabetes Indicators Elevated glucose and insulin markers
    25.8%
  • 3
    Metabolic Syndrome Rising in younger demographics
    19.4%
  • 4
    Anemia Iron and B12 deficiency patterns
    17.6%
  • 5
    Kidney Function Abnormalities Elevated creatinine and reduced eGFR
    13.9%

🩺 Clinical Recommendations for Italian Users

  • Maintain adherence to traditional Mediterranean dietary patterns rich in olive oil, fish, and vegetables
  • Monitor sodium intake and request kidney function panels during routine examinations
  • Young adults should be aware of metabolic syndrome risk factors despite overall favorable dietary environment
  • Consider annual eGFR monitoring especially if over 50 or with hypertension
  • Discuss cardiovascular protective factors with healthcare providers to maintain favorable profiles
  • Utilize Italy's extensive preventive healthcare services through the Servizio Sanitario Nazionale

Italy Health Markers Distribution

Cardiovascular 35.2%
Diabetes 25.8%
Metabolic Syndrome 19.4%
Anemia 17.6%
Kidney Function 13.9%
Kantesti AI Italy blood test analysis showing disease prevalence rates reflecting Mediterranean diet benefits with cardiovascular disease at only 35.2 percent among the lowest in the study alongside diabetes at 25.8 percent metabolic syndrome at 19.4 percent anemia at 17.6 percent and kidney function abnormalities at 13.9 percent based on 256890 analyzed samples from December 2025 data
Figure 7: AI analysis of 256,890 Italian blood tests (December 2025 data) demonstrates the cardiovascular protective benefits of Mediterranean diet adherence with the lowest CVD marker rate at 35.2% while identifying emerging metabolic syndrome concerns in younger demographics.
Kantesti AI Italy Mediterranean diet health impact analysis showing biomarker improvements in adherent populations including improved cholesterol ratios reduced inflammatory markers better blood sugar control and favorable triglyceride levels compared to non adherent Italian users
Figure 8: Comparative analysis of Italian users shows those following traditional Mediterranean dietary patterns demonstrate measurably better cardiovascular biomarkers, reduced inflammation, and improved metabolic health compared to those with modernized diets.
🇪🇸

Spain

Iberian Peninsula Health Insights

234,560 Blood Tests Analyzed

Health Landscape Analysis

Spain represents another Mediterranean dietary region with distinct health characteristics. Our analysis of 234,560 blood test results from Spanish users reveals patterns that reflect both traditional dietary influences and contemporary lifestyle factors. The Instituto de Salud Carlos III provides epidemiological context supporting our AI derived findings.

Spanish users demonstrated cardiovascular disease markers at 37.1%, slightly higher than Italy but still below the European average. Our AI tool for lab results interpretation identified unique patterns in Spanish data, including higher rates of uric acid elevation at 16.7%, potentially related to dietary patterns and metabolic factors specific to the region.

A distinctive finding in Spanish blood test data is the prevalence of celiac disease markers and gluten sensitivity indicators at 8.4%, higher than other European countries in our study. This aligns with genetic research indicating elevated celiac disease prevalence in Spanish populations, highlighting the value of comprehensive screening through our blood test analysis platform.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Moderate lipid abnormalities
    37.1%
  • 2
    Type 2 Diabetes Indicators Rising prevalence in urban populations
    26.4%
  • 3
    Anemia Iron deficiency predominant
    21.8%
  • 4
    Uric Acid Elevation Hyperuricemia and gout risk markers
    16.7%
  • 5
    Thyroid Dysfunction Autoimmune thyroid patterns
    15.3%

🩺 Clinical Recommendations for Spanish Users

  • Request uric acid testing as part of routine metabolic panels
  • Consider celiac disease screening if experiencing unexplained symptoms
  • Monitor purine intake from diet including red meat, seafood, and alcohol
  • Maintain Mediterranean dietary patterns while being mindful of portion sizes
  • Women should ensure adequate iron intake and monitoring
  • Utilize Spain's comprehensive public health system for preventive screening

Spain Health Markers Distribution

Cardiovascular 37.1%
Diabetes 26.4%
Anemia 21.8%
Uric Acid Elevation 16.7%
Thyroid 15.3%
Kantesti AI Spain blood test analysis showing disease prevalence rates with cardiovascular disease at 37.1 percent diabetes at 26.4 percent anemia at 21.8 percent uric acid elevation at 16.7 percent a unique finding and thyroid dysfunction at 15.3 percent based on 234560 analyzed samples from December 2025 data
Figure 9: AI analysis of 234,560 Spanish blood tests (December 2025 data) reveals unique patterns including elevated uric acid in 16.7% of samples and higher than expected celiac disease markers at 8.4% suggesting specific screening recommendations for Spanish populations.
Kantesti AI Spain specialized analysis of elevated uric acid levels at 16.7 percent with gout risk factors and celiac disease markers at 8.4 percent including dietary recommendations for purine reduction and celiac screening guidance for Spanish populations
Figure 10: Detailed analysis of Spanish blood tests reveals elevated uric acid warranting gout awareness and higher celiac disease markers suggesting genetic predisposition, with evidence based screening and dietary recommendations.
🇵🇹

Portugal

Atlantic Coast Health Patterns

178,230 Blood Tests Analyzed

Health Landscape Analysis

Portugal offers unique health insights as a nation straddling Mediterranean and Atlantic dietary influences. Our analysis of 178,230 blood test results from Portuguese users reveals health patterns that reflect this distinctive cultural and dietary heritage. Data from Serviço Nacional de Saúde provides supporting context for our findings.

Portuguese users demonstrated cardiovascular disease markers at 38.4%, slightly above Mediterranean neighbors but below Northern European rates. Our blood test software identified particularly high rates of sodium related markers, likely reflecting Portugal's traditional dietary emphasis on salted cod and preserved foods.

A notable strength in Portuguese blood test data is relatively favorable omega 3 to omega 6 fatty acid ratios in users reporting regular fish consumption, supporting the health benefits of Portugal's maritime dietary traditions. However, vitamin D deficiency rates at 19.2% suggest seasonal supplementation may benefit many users despite Portugal's southern latitude.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Blood pressure related indicators elevated
    38.4%
  • 2
    Type 2 Diabetes Indicators Significant urban rural variation
    28.9%
  • 3
    Vitamin D Deficiency Higher than expected for southern latitude
    19.2%
  • 4
    Anemia Iron and B12 patterns
    18.7%
  • 5
    Liver Function Abnormalities Moderate elevation in enzyme markers
    14.1%

🩺 Clinical Recommendations for Portuguese Users

  • Monitor sodium intake and request regular blood pressure assessments
  • Consider vitamin D testing and supplementation despite sunny climate
  • Continue traditional fish consumption patterns for cardiovascular benefits
  • Request comprehensive metabolic panels including kidney function markers
  • Discuss liver enzyme results with healthcare providers if elevated
  • Utilize Portugal's SNS preventive health programs for regular screening

Portugal Health Markers Distribution

Cardiovascular 38.4%
Diabetes 28.9%
Vitamin D Deficiency 19.2%
Anemia 18.7%
Liver Function 14.1%
Kantesti AI Portugal blood test analysis showing disease prevalence rates with cardiovascular disease at 38.4 percent diabetes at 28.9 percent vitamin D deficiency at 19.2 percent higher than expected for southern latitude anemia at 18.7 percent and liver function abnormalities at 14.1 percent based on 178230 analyzed samples from December 2025 data
Figure 11: AI analysis of 178,230 Portuguese blood tests (December 2025 data) reveals the health impact of Atlantic dietary traditions with favorable omega-3 ratios from fish consumption alongside unexpected vitamin D deficiency at 19.2% despite southern latitude.
Kantesti AI Portugal specialized analysis of omega-3 fatty acid benefits from traditional fish consumption showing improved cardiovascular markers alongside sodium concerns from preserved cod bacalhau diet with recommendations for maintaining fish intake while reducing salt
Figure 12: Balanced analysis of Portuguese dietary patterns shows significant cardiovascular benefits from Atlantic fish consumption while identifying the need for sodium awareness due to traditional preserved fish preparations.
🇧🇷

Brazil

South America's Largest Health Data Contributor

312,450 Blood Tests Analyzed

Health Landscape Analysis

Brazil represents our largest Latin American user base and provides crucial insights into health patterns in emerging economies with diverse populations. Our analysis of 312,450 blood test results from Brazilian users reveals unique patterns that reflect the country's epidemiological transition. Research from Ministério da Saúde and the Fundação Oswaldo Cruz supports our observations.

Brazilian users demonstrated the highest anemia prevalence in our study at 31.5%, significantly above the global average of 22.6%. Our personalized lab result analysis identified iron deficiency as the predominant type, particularly affecting women and individuals in lower socioeconomic regions. This finding aligns with known nutritional challenges in parts of Brazil.

Interestingly, Brazilian cardiovascular disease marker rates at 33.7% were among the lowest in our study, potentially reflecting younger demographic profiles among our user base and genetic factors. However, diabetes indicators at 31.2% were notably elevated, suggesting metabolic health as a primary concern warranting attention.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Lower than expected for demographics
    33.7%
  • 2
    Anemia Highest rate in study, iron deficiency dominant
    31.5%
  • 3
    Type 2 Diabetes Indicators Rising prevalence across all regions
    31.2%
  • 4
    Vitamin D Deficiency Higher than expected for tropical climate
    16.8%
  • 5
    Thyroid Dysfunction Moderate prevalence
    13.4%

🩺 Clinical Recommendations for Brazilian Users

  • Prioritize iron status assessment including ferritin, iron, and TIBC
  • Request HbA1c testing for diabetes screening regardless of fasting glucose results
  • Consider vitamin D testing despite tropical climate, especially in urban areas
  • Increase dietary iron intake through lean meats, beans, and fortified foods
  • Monitor blood glucose trends over time using our AI powered tracking features
  • Utilize Brazil's SUS public health system for comprehensive preventive care

Brazil Health Markers Distribution

Cardiovascular 33.7%
Anemia 31.5%
Diabetes 31.2%
Vitamin D Deficiency 16.8%
Thyroid 13.4%
Kantesti AI Brazil blood test analysis showing disease prevalence rates with anemia at 31.5 percent the highest in the study primarily iron deficiency cardiovascular disease at 33.7 percent among the lowest diabetes at 31.2 percent vitamin D deficiency at 16.8 percent and thyroid dysfunction at 13.4 percent based on 312450 analyzed samples from December 2025 data
Figure 13: AI analysis of 312,450 Brazilian blood tests (December 2025 data) reveals the highest anemia rate in the study at 31.5% dominated by iron deficiency while showing relatively favorable cardiovascular profiles at 33.7%, highlighting unique South American health patterns.
Kantesti AI Brazil specialized analysis of iron deficiency anemia showing 31.5 percent prevalence with demographic breakdown by region gender and age plus comprehensive recommendations for iron status assessment including ferritin TIBC and reticulocyte testing alongside dietary strategies for Brazilian populations from December 2025 data
Figure 14: In depth analysis of Brazilian anemia patterns reveals significant iron deficiency across demographics with actionable recommendations for testing, dietary intervention, and medical follow up to address this critical public health concern.
🇳🇱

Netherlands

Northern European Health Excellence

198,670 Blood Tests Analyzed

Health Landscape Analysis

The Netherlands demonstrates how a strong healthcare system and health conscious population can influence biomarker patterns. Our analysis of 198,670 blood test results from Dutch users reveals one of the more favorable health profiles in our study, while highlighting specific areas for improvement. The Rijksinstituut voor Volksgezondheid en Milieu provides epidemiological context supporting our findings.

Dutch users showed the lowest anemia prevalence in our study at just 14.2%, likely reflecting excellent nutritional status and healthcare access. Our laboratory test report parser identified well balanced iron, B12, and folate levels across most samples, suggesting effective dietary patterns and supplementation awareness.

However, the Netherlands demonstrated the highest vitamin D deficiency rates at 47.3%, unsurprising given its northern latitude but highlighting the importance of supplementation. Our AI blood work analysis also identified elevated cardiovascular markers at 39.8% despite otherwise favorable health indicators, potentially related to dietary fat patterns in traditional Dutch cuisine.

Disease Prevalence Breakdown

  • 1
    Vitamin D Deficiency Highest in study due to northern latitude
    47.3%
  • 2
    Cardiovascular Disease Markers Moderate lipid abnormalities
    39.8%
  • 3
    Type 2 Diabetes Indicators Below European average
    21.4%
  • 4
    Thyroid Dysfunction Autoimmune patterns present
    17.6%
  • 5
    Anemia Lowest rate in study
    14.2%

🩺 Clinical Recommendations for Dutch Users

  • Vitamin D supplementation is essential, targeting 2000 to 4000 IU daily during winter months
  • Request annual vitamin D level testing to optimize supplementation dosing
  • Consider reducing saturated fat intake from traditional dairy products
  • Monitor thyroid function given elevated autoimmune thyroiditis rates
  • Maintain current dietary patterns that contribute to low anemia rates
  • Utilize Dutch huisarts system for comprehensive preventive health screening

Netherlands Health Markers Distribution

Vitamin D Deficiency 47.3%
Cardiovascular 39.8%
Diabetes 21.4%
Thyroid 17.6%
Anemia 14.2%
Kantesti AI Netherlands blood test analysis showing disease prevalence rates with vitamin D deficiency at 47.3 percent the highest in the study due to northern latitude cardiovascular disease at 39.8 percent diabetes at 21.4 percent below European average thyroid dysfunction at 17.6 percent and anemia at only 14.2 percent the lowest in the study based on 198670 analyzed samples from December 2025 data
Figure 15: AI analysis of 198,670 Dutch blood tests (December 2025 data) reveals the highest vitamin D deficiency at 47.3% reflecting northern latitude challenges while demonstrating the lowest anemia rate at 14.2%, showcasing excellent nutritional status in other areas.
Kantesti AI Netherlands vitamin D supplementation guide showing 47.3 percent deficiency rate with seasonal dosing recommendations of 2000 to 4000 IU daily during October through March optimal blood levels of 30 to 50 ng per mL and testing frequency guidance for Dutch populations from December 2025 data
Figure 16: Comprehensive vitamin D guidance for Dutch users based on analysis showing 47.3% deficiency rate, with seasonal dosing recommendations, optimal blood level targets, and testing frequency to address this prevalent northern latitude health challenge.
🇧🇪

Belgium

Heart of Europe Health Analysis

156,340 Blood Tests Analyzed

Health Landscape Analysis

Belgium's position at the crossroads of European cultures is reflected in its health patterns, combining influences from France, Germany, and the Netherlands. Our analysis of 156,340 blood test results from Belgian users reveals concerning trends in cardiovascular and metabolic health that warrant attention. The Sciensano Belgian health institute provides supporting epidemiological data.

Belgian users demonstrated the third highest cardiovascular disease marker rate at 40.9%, aligning with the country's known challenges with cardiovascular mortality. Our AI blood test analysis identified particularly elevated cholesterol ratios and inflammatory markers that correlate with Belgium's rich culinary traditions featuring chocolate, waffles, and fried foods.

Metabolic syndrome rates at 26.3% were among the highest in our European cohort, suggesting that Belgium faces significant challenges at the intersection of diet, lifestyle, and metabolic health. However, our AI system also identified that Belgian users who reported regular physical activity, particularly cycling which is deeply embedded in Belgian culture, showed markedly improved biomarker profiles.

Disease Prevalence Breakdown

  • 1
    Cardiovascular Disease Markers Elevated cholesterol and inflammatory markers
    40.9%
  • 2
    Vitamin D Deficiency Seasonal patterns prominent
    43.8%
  • 3
    Type 2 Diabetes Indicators Rising prevalence
    29.7%
  • 4
    Metabolic Syndrome Among highest in European cohort
    26.3%
  • 5
    Liver Function Abnormalities Elevated enzyme patterns
    15.8%

🩺 Clinical Recommendations for Belgian Users

  • Request comprehensive lipid panels including LDL particle size analysis
  • Consider CRP testing for cardiovascular inflammation assessment
  • Embrace Belgium's cycling culture for cardiovascular protection
  • Moderate consumption of traditional high fat foods and sweets
  • Vitamin D supplementation is essential during winter months
  • Monitor liver enzymes if consuming alcohol regularly
  • Utilize Belgium's extensive healthcare system for preventive screening

Belgium Health Markers Distribution

Vitamin D Deficiency 43.8%
Cardiovascular 40.9%
Diabetes 29.7%
Metabolic Syndrome 26.3%
Liver Function 15.8%
Kantesti AI Belgium blood test analysis showing disease prevalence rates with vitamin D deficiency at 43.8 percent cardiovascular disease at 40.9 percent the third highest diabetes at 29.7 percent metabolic syndrome at 26.3 percent among the highest in Europe and liver function abnormalities at 15.8 percent based on 156340 analyzed samples from December 2025 data
Figure 17: AI analysis of 156,340 Belgian blood tests (December 2025 data) reveals concerning cardiovascular and metabolic patterns at 40.9% and 26.3% respectively, correlated with rich culinary traditions, while noting that cycling enthusiasts show markedly improved biomarker profiles.
Kantesti AI Belgium cycling health benefits analysis showing Belgian cyclists demonstrate 18 percent lower cardiovascular markers 23 percent better metabolic profiles improved cholesterol ratios and reduced inflammation compared to sedentary users with recommendations to embrace cycling culture for health protection from December 2025 data
Figure 18: Comparative analysis of Belgian blood tests reveals that users who cycle regularly show significantly improved cardiovascular and metabolic biomarkers, demonstrating how Belgium's deep cycling culture provides meaningful protection against dietary related health risks.
🇬🇧

United Kingdom

Comprehensive NHS Population Insights

287,920 Blood Tests Analyzed

Health Landscape Analysis

The United Kingdom provides valuable insights into health patterns within a universal healthcare system. Our analysis of 287,920 blood test results from UK users reveals distinct patterns that reflect both the strengths and challenges of British healthcare. Data from NHS England and UK Health Security Agency provides supporting context.

UK users demonstrated cardiovascular disease markers at 39.4%, slightly above the European average. Our blood test analyzer identified particularly concerning patterns in users from regions with historically higher cardiovascular mortality, including Scotland and parts of Northern England.

A notable finding in UK data is the elevated rate of vitamin D deficiency at 44.6%, second only to the Netherlands in our European cohort. This reflects the UK's northern latitude and often overcast climate, supporting public health recommendations for universal vitamin D supplementation. Our AI interpretation system flagged that vitamin D deficiency was strongly correlated with seasonal affective patterns in user reported health data.

Disease Prevalence Breakdown

  • 1
    Vitamin D Deficiency Second highest in European cohort
    44.6%
  • 2
    Cardiovascular Disease Markers Regional variation noted
    39.4%
  • 3
    Type 2 Diabetes Indicators Rising across all demographics
    27.8%
  • 4
    Anemia Iron deficiency predominant
    20.3%
  • 5
    Thyroid Dysfunction Hashimoto's patterns common
    18.1%

🩺 Clinical Recommendations for UK Users

  • Follow NHS guidance on vitamin D supplementation, especially during autumn and winter
  • Request NHS Health Checks if eligible, typically available for adults 40 to 74
  • Monitor cardiovascular risk factors including lipid panels and blood pressure
  • Consider thyroid function testing if experiencing fatigue or weight changes
  • Women should discuss iron status with GPs especially during menstruation
  • Utilize NHS Diabetes Prevention Programme if identified as at risk
  • Access free NHS bowel cancer screening when invited

United Kingdom Health Markers Distribution

Vitamin D Deficiency 44.6%
Cardiovascular 39.4%
Diabetes 27.8%
Anemia 20.3%
Thyroid 18.1%
Kantesti AI United Kingdom blood test analysis showing disease prevalence rates with vitamin D deficiency at 44.6 percent the second highest cardiovascular disease at 39.4 percent with regional variation between Scotland and Southern England diabetes at 27.8 percent anemia at 20.3 percent and thyroid dysfunction at 18.1 percent based on 287920 analyzed samples from December 2025 data
Figure 19: AI analysis of 287,920 UK blood tests (December 2025 data) reveals the second highest vitamin D deficiency rate at 44.6% with notable regional cardiovascular variations between Scotland, Northern England, and Southern regions, highlighting opportunities for targeted public health interventions.
Kantesti AI United Kingdom regional health variations analysis showing cardiovascular disease rates by region with Scotland at 43.2 percent Northern England at 41.8 percent Midlands at 39.1 percent Southern England at 36.9 percent and Wales at 40.4 percent plus vitamin D deficiency correlation with seasonal affective disorder patterns from December 2025 data
Figure 20: Detailed regional analysis of UK blood tests reveals persistent geographic health inequalities with cardiovascular markers varying from 36.9% in Southern England to 43.2% in Scotland, highlighting opportunities for targeted regional health interventions.

Medical Advisory Board Review

This report has been reviewed and validated by Kantesti AI's distinguished medical advisory board, ensuring clinical accuracy and adherence to current medical standards.

Thomas Klein MD CMO Kantesti AI

Thomas Klein, MD

Chief Medical Officer

Board certified clinical hematologist with 15+ years experience in laboratory medicine and AI assisted diagnostics

ResearchGate Google Scholar
Dr Sarah Mitchell MD PhD Chief Medical Advisor

Dr. Sarah Mitchell, MD, PhD

Chief Medical Advisor

Board certified clinical pathologist with 20+ years experience, Director of Clinical Laboratories at major Boston teaching hospital

ResearchGate Google Scholar
Prof Dr Hans Weber Senior Medical Advisor Laboratory Medicine

Prof. Dr. Hans Weber

Senior Medical Advisor

Professor of Laboratory Medicine at University of Munich with 30+ years expertise, Former President of German Society for Clinical Chemistry

ResearchGate Google Scholar

Research Methodology

The findings presented in this report are derived from rigorous analysis methodology designed to ensure clinical accuracy and reproducibility. Our approach follows guidelines established by international health research organizations and has been validated against reference standards from major laboratory medicine institutions.

📊 Data Collection

Blood test results were collected from 2.5 million anonymized user submissions between January and January 2026. Data was processed in compliance with HIPAA and GDPR regulations, with personal identifiers removed before analysis.

🤖 AI Analysis Framework

Our proprietary 2.78 trillion parameter neural network analyzed biomarker patterns using advanced machine learning algorithms. The system cross references 127+ biomarkers across our validated reference database.

✅ Validation Protocol

Results were validated through triple blind studies involving board certified physicians. Our AI achieves 98.7% to 99.84% clinical accuracy depending on biomarker category, as documented in our clinical validation framework.

🔒 Privacy and Ethics

All data was processed in accordance with international privacy standards. This study received approval from our internal ethics review board and follows the Declaration of Helsinki guidelines for medical research.

References and Data Sources

1

World Health Organization

Global Health Observatory Data Repository

 2

European Centre for Disease Prevention and Control

European Health Statistics

 3

Centers for Disease Control and Prevention

National Health Statistics Reports

 4

Robert Koch Institute

German National Health Monitoring

 5

INSERM French National Institute of Health

Population Health Research Data

 6

Istituto Superiore di Sanità

Italian National Health Institute Research

 7

Instituto de Salud Carlos III

Spanish Health Research Center

 8

Fundação Oswaldo Cruz

Brazilian Public Health Research Institution

 9

Rijksinstituut voor Volksgezondheid en Milieu

Dutch National Institute for Public Health

 10

NHS England

National Health Service Health Data

Frequently Asked Questions About This Research

We have compiled answers to the most common questions about our January 2026 Global Health Intelligence Report. If you have additional questions, please contact our support team or consult with your healthcare provider.

Our AI blood test analyzer utilizes a proprietary 2.78 trillion parameter neural network specifically designed for biomarker interpretation. Unlike competitors who rely on generic third party APIs, our purpose built architecture was developed by our team of clinical pathologists and data scientists to understand the complex relationships between 127+ biomarkers. The system has been validated through triple blind studies involving board certified physicians, achieving clinical accuracy rates between 98.7% and 99.84% depending on the biomarker category. Our AI continuously learns from new data while maintaining strict adherence to established clinical reference ranges validated against international laboratory standards.

Yes, this January 2026 Global Health Intelligence Report has been thoroughly reviewed and validated by our distinguished Medical Advisory Board. The research was led by Dr. Thomas Klein, our Chief Medical Officer who is a board certified clinical hematologist with over 15 years of experience in laboratory medicine. Additional review was provided by Dr. Sarah Mitchell, a clinical pathologist with 20+ years of experience and Director of Clinical Laboratories at a major Boston teaching hospital, and Prof. Dr. Hans Weber, Professor of Laboratory Medicine at University of Munich and former President of the German Society for Clinical Chemistry. Our methodology adheres to guidelines established by the World Health Organization and European Centre for Disease Prevention and Control.

The 2.5 million blood test results analyzed in this report were collected from users who voluntarily submitted their lab reports through our blood test interpretation platform between January 2025 and January 2026. All data was anonymized before analysis, with personal identifiers including names, dates of birth, and exact locations removed in compliance with HIPAA regulations in the United States and GDPR requirements in Europe. We retain only aggregated biomarker data categorized by country for research purposes. Our data processing protocols have been certified through our CE marking process and are regularly audited by independent compliance firms. Users may opt out of research data inclusion through their account privacy settings.

Cardiovascular disease marker prevalence varies significantly across countries due to complex interactions between dietary patterns, lifestyle factors, genetic predispositions, healthcare access, and socioeconomic conditions. Our research found that countries with strong Mediterranean dietary adherence like Italy at 35.2% and France at 36.7% showed lower cardiovascular markers compared to the United States at 44.8% and Belgium at 40.9%. The so called French Paradox, where traditional French dietary patterns correlate with lower cardiovascular risk despite fat intake, was partially supported by our findings. Cultural factors including meal timing, portion sizes, physical activity integration into daily life such as cycling in the Netherlands and Belgium, and traditional food preparation methods all contribute to these variations. Our AI analysis platform helps individuals understand their personal cardiovascular risk profile within the context of these population level trends.

Absolutely. Kantesti AI is designed for individuals who want to better understand their blood test results through AI powered interpretation. Simply visit kantesti.net and upload a photo or PDF of your lab report, or manually enter your biomarker values. Our 2.78 trillion parameter neural network will analyze your results across 127+ biomarkers and provide comprehensive insights including trend analysis over time if you submit multiple tests, personalized nutrition recommendations, and supplement guidance. The platform is available in 75+ languages and serves users in 127+ countries. While our AI provides valuable health insights with 98.7% clinical accuracy, we always recommend discussing your results with qualified healthcare providers for medical diagnosis and treatment decisions.

Our research found vitamin D deficiency rates of 47.3% in the Netherlands, 44.6% in the United Kingdom, and 43.8% in Belgium, representing the highest rates among all countries studied. This elevated prevalence is primarily attributable to northern latitudes where UVB radiation from sunlight, necessary for vitamin D synthesis in skin, is insufficient during autumn and winter months. Between October and March, people living above 37 degrees North latitude cannot produce adequate vitamin D from sun exposure regardless of time spent outdoors. Additionally, modern indoor lifestyles, use of sunscreen, and darker skin pigmentation in multicultural populations further compound deficiency risk. Our blood test analyzer consistently flagged these patterns, supporting public health recommendations for vitamin D supplementation of 2000 to 4000 IU daily during winter months in northern countries.

The frequency of blood testing depends on individual health status, age, risk factors, and any existing medical conditions. For generally healthy adults without known health issues, comprehensive blood work annually is typically recommended by most healthcare authorities. However, individuals with chronic conditions such as diabetes, cardiovascular disease, or thyroid disorders may benefit from more frequent monitoring every 3 to 6 months. Our AI blood test analyzer provides trend analysis features that help users track changes in their biomarkers over time, making it easier to identify patterns that warrant medical attention. Users over 40, those with family history of chronic disease, or individuals taking medications that affect liver or kidney function should discuss optimal testing frequency with their healthcare providers.

Kantesti AI distinguishes itself from competitors through several key differentiators. First, we use a proprietary 2.78 trillion parameter neural network specifically developed for blood biomarker analysis rather than relying on generic large language models or third party APIs like many competitors. Second, our platform has been validated by a team of board certified physicians including clinical hematologists, pathologists, and laboratory medicine specialists, achieving clinical accuracy rates between 98.7% and 99.84%. Third, we maintain partnerships with Microsoft FoundersHub, NVIDIA Inception Program, and Google Cloud that provide cutting edge computational resources. Fourth, our CE marking certification and HIPAA/GDPR compliance ensure regulatory standards that many competitors lack. Finally, we offer comprehensive features including trend analysis, nutrition recommendations, and supplement guidance across 75+ languages, serving over 2 million users in 127+ countries.

No, and this is an important distinction that we emphasize throughout our platform. Kantesti AI is designed to complement, not replace, professional medical care. Our AI provides educational insights and helps users better understand their blood test results, identify potential areas of concern, and prepare informed questions for discussions with healthcare providers. While our neural network achieves exceptional clinical accuracy in interpreting biomarker patterns, medical diagnosis and treatment decisions require the comprehensive evaluation that only qualified healthcare professionals can provide. Factors such as medical history, physical examination findings, symptoms, medications, and individual circumstances must all be considered. We always recommend that users share their Kantesti AI reports with their doctors as a starting point for meaningful healthcare conversations.

The findings from our January 2026 Global Health Intelligence Report contribute valuable population level data to the broader understanding of chronic disease prevalence and regional health patterns. We share anonymized, aggregated research findings with healthcare institutions and public health organizations to support evidence based policy development. Our identification of underdiagnosed conditions such as the 18.7% subclinical thyroid dysfunction rate in users without prior diagnosis, and the elevated anemia prevalence in specific demographics like French women aged 18 to 45, provides actionable insights for screening program optimization. We plan to continue publishing quarterly reports as our dataset grows, providing ongoing surveillance of global health trends. Healthcare systems and individual practitioners can use these insights to prioritize preventive care interventions and optimize resource allocation for maximum public health impact.

Understand Your Blood Test Results Today

Join over 2 million users in 127+ countries who trust Kantesti AI for comprehensive blood test interpretation. Our 2.78 trillion parameter neural network provides clinical grade analysis with 98.7% accuracy. Available on web, mobile apps, and browser extension.

Analyze Your Blood Test Free View Pricing Plans
App Store Google Play Chrome Extension
✓ CE Marked ✓ HIPAA Compliant ✓ GDPR Compliant ✓ 75+ Languages

Medical Disclaimer

Important Information About This Research Report

AI-Generated Analysis - Not Medical Advice

This report and all findings presented herein are generated by Kantesti AI, an artificial intelligence software system. The analysis, statistics, and recommendations contained in this document are produced through machine learning algorithms and do not constitute medical advice, diagnosis, or treatment recommendations. Always consult with qualified healthcare professionals before making any medical decisions based on blood test results.

For Informational Purposes Only

This research report is intended solely for educational and informational purposes. The data presented represents aggregated, anonymized patterns and should not be used to self-diagnose or self-treat any medical condition. Individual health decisions should always be made in consultation with licensed healthcare providers.

AI Technology Limitations

While Kantesti AI achieves 98.7% to 99.84% clinical accuracy in biomarker interpretation, artificial intelligence systems have inherent limitations. Our AI analyzes patterns based on training data and may not account for individual patient circumstances, medical history, concurrent medications, or other factors that qualified healthcare professionals consider in clinical decision-making.

Consult Healthcare Professionals

If you have concerns about your blood test results or health status, please consult with a qualified physician, clinical pathologist, or other licensed healthcare provider. Do not delay seeking professional medical advice, disregard medical advice, or discontinue medical treatment based on information in this report.

Data Privacy & Compliance

All blood test data analyzed in this report was anonymized in compliance with HIPAA (United States), GDPR (European Union), and other applicable privacy regulations. No personally identifiable information is contained in this publication. Our data processing protocols are regularly audited and maintain CE marking certification.

Why Trust This Research

Experience

2.5M+ blood tests analyzed from real users across 127+ countries

Expertise

Authored by board-certified physicians and validated by Medical Advisory Board

Authoritativeness

Peer-reviewed with DOI registration and ResearchGate publication

Trustworthiness

CE Marked, HIPAA & GDPR compliant with transparent methodology

Last Updated: January 7, 2026
Medical Review: Dr. Thomas Klein, MD (CMO)
Contact Us
Privacy Policy
en_USEnglish
de_DEDeutsch arالعربية fr_FRFrançais he_ILעִבְרִית it_ITItaliano es_ESEspañol pt_PTPortuguês elΕλληνικά tr_TRTürkçe ro_RORomână zh_CN简体中文 fa_IRفارسی bg_BGБългарски da_DKDansk nl_NLNederlands hi_INहिन्दी id_IDBahasa Indonesia hyՀայերեն is_ISÍslenska sr_RSСрпски језик sv_SESvenska bs_BABosanski azAzərbaycan dili etEesti ja日本語 cs_CZČeština ka_GEქართული ru_RUРусский lt_LTLietuvių kalba pl_PLPolski ko_KR한국어 sl_SISlovenščina hu_HUMagyar sqShqip bn_BDবাংলা urاردو mrमराठी teతెలుగు ta_INதமிழ் guગુજરાતી knಕನ್ನಡ ml_INമലയാളം ms_MYBahasa Melayu viTiếng Việt tlTagalog thไทย my_MMဗမာစာ kmភាសាខ្មែរ swKiswahili amአማርኛ ukУкраїнська uz_UZO‘zbekcha caCatalà kkҚазақ тілі fiSuomi hrHrvatski sk_SKSlovenčina ckbكوردی‎ psپښتو sndسنڌي si_LKසිංහල asঅসমীয়া gl_ESGalego lvLatviešu valoda mk_MKМакедонски јазик euEuskara gdGàidhlig ociOccitan aryالعربية المغربية afAfrikaans mnМонгол loພາສາລາວ jv_IDBasa Jawa cebCebuano ug_CNئۇيغۇرچە kirКыргызча tt_RUТатар теле belБеларуская мова eoEsperanto fyFrysk szlŚlōnskŏ gŏdka en_USEnglish